Genzyme CEO Discusses Benefits Of High-Priced Medications For Rare Diseases In NYT Letter To The Editor

“Rather than fear the cost impact” of the development of medications for rare diseases that “are among the first personalized medicines,” as a March 16 article and a March 23 editorial in the New York Times indicated, “we should embrace its potential to redirect resources toward treatments that work more effectively and safely because they are prescribed only to those patients most likely to benefit,”

More: continued here

Filed under: Health Insurance / Medical Insurance on April 2nd, 2008